Aquestive Therapeutics Share Price (NASDAQ: AQST)

$3.77

▲

-0.06

(-1.57%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Aquestive Therapeutics Stock chart to analyse performance

Aquestive Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$3.74
Today's High:$3.85
$3.77
0.8%
Downside
Day's Volatility :2.73%
Upside
1.95%
52 Weeks Low:$2.12
52 Weeks High:$5.80
$3.77
43.77%
Downside
52 Weeks Volatility :63.45%
Upside
35.0%

Aquestive Therapeutics Stock Returns

Period	Aquestive Therapeutics Inc	Index (Russel 2000)
3 Months	34.52%	0.0%
6 Months	42.64%	0.0%
1 Year	-16.56%	0.0%
3 Years	161.59%	-4.7%

Aquestive Therapeutics Inc Key Stats

Check Aquestive Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$3.83
Open	$3.81
Today's High	$3.845
Today's Low	$3.74
Market Capitalization	$456.1M
Today's Volume	$1.0M
52 Week High	$5.8
52 Week Low	$2.12
Revenue TTM	$44.1M
EBITDA	$-52.0M
Earnings Per Share (EPS)	$-0.69
Profit Margin	-147.38%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	0.0%

Stock Returns calculator for Aquestive Therapeutics Stock including INR - Dollar returns

The Aquestive Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Aquestive Therapeutics investment value today

Current value as on today

₹88,507

Returns

₹11,493

(-11.49%)

Returns from Aquestive Therapeutics Stock

₹16,777 (-16.78%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Aquestive Therapeutics Stock

Period: Jul 30, 2025 to Aug 29, 2025. Change in 30 Days versus previous period

Search interest for Aquestive Therapeutics Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Aquestive Therapeutics Inc

Name
Holdings %
Name
Holdings %
Bratton Capital Management, L.P.
9.87%
BlackRock Inc
5.97%
Vanguard Group Inc
4.36%
Perceptive Advisors LLC
2.20%
Geode Capital Management, LLC
1.71%
Pale Fire Capital SE
1.69%

Analyst Recommendation on Aquestive Therapeutics Stock

Rating

Trend

Buy

92%Buy

7%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Aquestive Therapeutics(by analysts ranked 0 to 5 stars)

Aquestive Therapeutics Share Price Target

What analysts predicted

Upside of 123.25%

Target:

$8.42

Current:

$3.77

Aquestive Therapeutics share price target is $8.42, a slight Upside of 123.25% compared to current price of $3.77 as per analysts' prediction.

Aquestive Therapeutics Stock Insights

Price Movement
In the last 3 years, AQST stock has moved up by 148.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 8.72M → 10.00M (in $), with an average increase of 12.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -22.93M → -13.54M (in $), with an average increase of 69.3% per quarter
AQST vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 26.5%
Price to Sales
ForAQST every $1 of sales, investors are willing to pay $8.1, whereas for Neurocrine Biosciences Inc., the investors are paying $5.6 for every $1 of sales.

Aquestive Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$52.6M	↓ 21.98%
Net Income	$-66.2M	↑ 7.93%
Net Profit Margin	-125.92%	↓ 34.9%

	FY20	Y/Y Change
Revenue	$45.8M	↓ 12.85%
Net Income	$-55.8M	↓ 15.79%
Net Profit Margin	-121.67%	↑ 4.25%

	FY21	Y/Y Change
Revenue	$50.8M	↑ 10.87%
Net Income	$-70.5M	↑ 26.45%
Net Profit Margin	-138.77%	↓ 17.1%

	FY22	Y/Y Change
Revenue	$47.7M	↓ 6.2%
Net Income	$-54.4M	↓ 22.87%
Net Profit Margin	-114.11%	↑ 24.66%

	FY23	Y/Y Change
Revenue	$50.6M	↑ 6.09%
Net Income	$-7.9M	↓ 85.54%
Net Profit Margin	-15.56%	↑ 98.55%

	FY24	Y/Y Change
Revenue	$57.6M	↑ 13.8%
Net Income	$-44.1M	↑ 460.83%
Net Profit Margin	-76.68%	↓ 61.12%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$12.1M	↓ 8.73%
Net Income	$-12.8M	↑ 58.16%
Net Profit Margin	-106.43%	↓ 45.01%

	Q2 FY24	Q/Q Change
Revenue	$20.1M	↑ 66.76%
Net Income	$-2.7M	↓ 78.6%
Net Profit Margin	-13.66%	↑ 92.77%

	Q3 FY24	Q/Q Change
Revenue	$13.5M	↓ 32.62%
Net Income	$-11.5M	↑ 319.27%
Net Profit Margin	-84.99%	↓ 71.33%

	Q4 FY24	Q/Q Change
Revenue	$11.9M	↓ 12.37%
Net Income	$-17.1M	↑ 48.19%
Net Profit Margin	-143.72%	↓ 58.73%

	Q1 FY25	Q/Q Change
Revenue	$8.7M	↓ 26.52%
Net Income	$-22.9M	↑ 34.45%
Net Profit Margin	-262.96%	↓ 119.24%

	Q2 FY25	Q/Q Change
Revenue	$10.0M	↑ 14.71%
Net Income	$-13.5M	↓ 40.92%
Net Profit Margin	-135.44%	↑ 127.52%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$32.2M	↓ 30.56%

	FY20	Y/Y Change
Profit	$32.9M	↑ 1.98%

	FY21	Y/Y Change
Profit	$35.8M	↑ 8.99%

	FY22	Y/Y Change
Profit	$28.3M	↓ 21.06%

	FY23	Y/Y Change
Profit	$29.8M	↑ 5.15%

	FY24	Y/Y Change
Profit	$39.7M	↑ 33.4%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$7.7M	↓ 10.12%

	Q2 FY24	Q/Q Change
Profit	$15.6M	↑ 103.2%

	Q3 FY24	Q/Q Change
Profit	$9.1M	↓ 41.53%

	Q4 FY24	Q/Q Change
Profit	$7.3M	↓ 19.31%

	Q1 FY25	Q/Q Change
Profit	$5.1M	↓ 31.02%

	Q2 FY25	Q/Q Change
Profit	$5.4M	↑ 7.38%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-60.2M	↑ 363.47%
Investing Cash Flow	$-663.0K	↓ 63.65%
Financing Cash Flow	$49.6M	↓ 14.53%

	FY20	Y/Y Change
Operating Cash Flow	$-45.5M	↓ 24.5%
Investing Cash Flow	$-517.0K	↓ 22.02%
Financing Cash Flow	$28.5M	↓ 42.63%

	FY21	Y/Y Change
Operating Cash Flow	$-33.0M	↓ 27.45%
Investing Cash Flow	$-913.0K	↑ 76.6%
Financing Cash Flow	$30.1M	↑ 5.81%

	FY22	Y/Y Change
Operating Cash Flow	$-9.8M	↓ 70.32%
Investing Cash Flow	$-2.5M	↑ 176.45%
Financing Cash Flow	$11.6M	↓ 61.6%

	FY23	Y/Y Change
Operating Cash Flow	$-6.4M	↓ 34.82%
Investing Cash Flow	$-995.0K	↓ 60.58%
Financing Cash Flow	$4.0M	↓ 65.63%

	FY24	Y/Y Change
Operating Cash Flow	$-35.8M	↑ 460.49%
Investing Cash Flow	$-159.0K	↓ 84.02%
Financing Cash Flow	$83.6M	↑ 2003.47%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-10.4M	↑ 110.12%
Investing Cash Flow	$-29.0K	↑ 81.25%
Financing Cash Flow	$81.7M	↑ 1988.96%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-7.0M	↓ 32.53%
Investing Cash Flow	$-35.0K	↑ 20.69%
Financing Cash Flow	$1.7M	↓ 97.91%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-11.9M	↑ 69.57%
Investing Cash Flow	$-80.0K	↑ 128.57%
Financing Cash Flow	$-17.0K	↓ 100.99%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-6.5M	↓ 45.38%
Investing Cash Flow	$-15.0K	↓ 81.25%
Financing Cash Flow	$157.0K	↓ 1023.53%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-23.4M	↑ 260.61%
Investing Cash Flow	$-135.0K	↑ 800.0%
Financing Cash Flow	$20.6M	↑ 13050.32%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-7.9M	↓ 66.18%
Investing Cash Flow	$-107.0K	↓ 20.74%
Financing Cash Flow	$-100.0K	↓ 100.48%

Aquestive Therapeutics Technicals Summary

Sell

Neutral

Buy

Aquestive Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Aquestive Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Aquestive Therapeutics Inc	-1.56%	42.64%	-16.56%	161.59%	-51.91%
Haleon Plc Spon Ads	3.98%	-7.33%	-3.68%	63.96%	32.32%
United Therapeutics Corporation	10.96%	-1.69%	-16.16%	34.5%	71.41%
Zoetis Inc.	7.28%	-8.28%	-14.76%	-0.08%	-2.3%
Neurocrine Biosciences Inc.	8.87%	21.94%	9.87%	33.42%	19.91%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Aquestive Therapeutics Inc	NA	NA	NA	-0.59	0.0	-0.31	NA	-0.73
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Aquestive Therapeutics Inc	Buy	$456.1M	-51.91%	NA	-147.38%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-2.3%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	19.91%	41.3	13.88%

About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Organization	Aquestive Therapeutics
Employees	142
CEO	Mr. Daniel Barber
Industry	Health Technology

Key Management of Aquestive Therapeutics Inc

Name	Title
Mr. Daniel Barber	CEO, President & Director
Ms. Lori J. Braender BSBA, Esq., J.D.	Chief Legal Officer, Chief Compliance Officer & Secretary
Mr. A. Ernest Toth Jr.	Chief Financial Officer
Ms. Cassie Jung	Chief Operating Officer
Mr. Peter E. Boyd	Senior Vice President of Information Technology & Human Resources
Dr. Gary H. Slatko M.D., MBA	Chief Medical Officer
Dr. Carl N. Kraus M.D.	Chief Medical Officer
Ms. Sherry Korczynski	Chief Commercial Officer
Dr. Melina T. Cioffi Pharm.D.	Senior Vice President of Regulatory Affairs
Mr. Robert Charles Arnold	VP of Finance, Controller & Assistant Secretary

Important FAQs about investing in AQST Stock from India :

What is Aquestive Therapeutics share price today?

Aquestive Therapeutics share price today is $3.77 as on August 30, 2025 at 1:29 am IST at the close of the market. Aquestive Therapeutics share today touched a day high of $3.85 and a low of $3.74.

What is the 52 week high and 52 week low for Aquestive Therapeutics share?

Aquestive Therapeutics share touched a 52 week high of $5.80 and a 52 week low of $2.12. Aquestive Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $3.77, lower by 35% versus the 52 week high.

How to invest in Aquestive Therapeutics Stock (AQST) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Aquestive Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aquestive Therapeutics Shares that will get you 0.3979 shares as per Aquestive Therapeutics share price of $3.77 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Aquestive Therapeutics Stock (AQST) from India?

Indian investors can start investing in Aquestive Therapeutics (AQST) shares with as little as ₹88.286 or $1 (as of August 30, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Aquestive Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 30, 2025). Based on Aquestive Therapeutics share’s latest price of $3.77 as on August 30, 2025 at 1:29 am IST, you will get 2.6525 shares of Aquestive Therapeutics. Learn more about fractional shares .

What are the returns that Aquestive Therapeutics has given to Indian investors in the last 5 years?

Aquestive Therapeutics stock has given -51.91% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?